Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapyKendrick Yim, Mark A. Preston, Kevin Melnick et al.|Urologic Oncology Seminars and Original Investigations|2023Cited by 31
Prostate Cancer Risk and DNA Mismatch Repair Deficiency Among Lynch Syndrome PatientsLinda Rodgers, Keyan Salari, Chin‐Lee Wu et al.|European Urology Open Science|2025Cited by 1